WASHINGTON, D.C. – Phyllis Arthur, Executive Vice President and Head of Health Policy and Programs of the Biotechnology Innovation Organization (BIO) released the following statement on the December ...

WASHINGTON, D.C. – The Biotechnology Innovation Organization (BIO) released the following statement on today’s passage of the Mikaela Naylon Give Kids a Chance Act in the House of Representatives.

Since Watson and Crick discovered DNA's double helix structure in 1953, the US has been a leader in biotechnology innovation. American excellence in this field has greatly benefited people around the ...

Every year, JPM Healthcare Week sets the pace for biotech deal-making. But the skills and insights you gain from preparing for high stakes partnering meetings are valuable long after January. In this ...

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic ...

Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare ...

BIO President & CEO John F. Crowley announced today that BIO would take several important steps to reaffirm the organization’s position with regards to national security and the role that the industry ...

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on the potential for 100% tariffs on branded or patented ...

WASHINGTON, D.C. - John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding today’s dismissal of the voting members of the CDC ...

Democratic lawmakers in the U.S. Senate advanced drug pricing legislation today that would drastically alter the Medicare program. Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology ...

John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the FDA: “Under the extraordinary ...

Today, the Biotechnology Innovation Organization (BIO) released a new report, "The State of Innovation in Vaccines and Prophylactic Antibodies for Infectious Diseases," examining the latest scientific ...